Neurobiology of Disease (Nov 2011)

Olfactory neuron-specific expression of A30P alpha-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages

  • Silke Nuber,
  • Elisabeth Petrasch-Parwez,
  • Oscar Arias-Carrión,
  • Leanie Koch,
  • Zacharias Kohl,
  • Jacqueline Schneider,
  • Carsten Calaminus,
  • Rolf Dermietzel,
  • Anna Samarina,
  • Jana Boy,
  • Huu P. Nguyen,
  • Peter Teismann,
  • Thirumalaisamy Palanichamy Velavan,
  • Philipp J. Kahle,
  • Stephan von Hörsten,
  • Markus Fendt,
  • Rejko Krüger,
  • Olaf Riess

Journal volume & issue
Vol. 44, no. 2
pp. 192 – 204

Abstract

Read online

Mutations in the N-terminus of the gene encoding α-synuclein (α-syn) are linked to autosomal dominantly inherited Parkinson's disease (PD). The vast majority of PD patients develop neuropsychiatric symptoms preceding motor impairments. During this premotor stage, synucleinopathy is first detectable in the olfactory bulb (OB) and brain stem nuclei; however its impact on interconnected brain regions and related symptoms is still less far understood. Using a novel conditional transgenic mouse model, displaying region-specific expression of human mutant α-syn, we evaluated effect and reversibility of olfactory synucleinopathy. Our data showed that induction of mutant A30P α-syn expression increased transgenic deposition into somatodendritic compartment of dopaminergic neurons, without generating fibrillar inclusions. We found reversibly reduced levels of dopamine and metabolites in the OB, suggesting an impact of A30P α-syn on olfactory neurotransmitter content. We further showed that mutant A30P expression led to neurodegenerative changes on an ultrastructural level and a behaviorally hyperactive response correlated with novelty, odor processing and stress associated with an increased dopaminergic tone in midbrain regions. Our present data indicate that mutant (A30P) α-syn is directly implicated in reduction of dopamine signaling in OB interneurons, which mediates further alterations in brain regions without transgenic expression leading functionally to a hyperactive response. These modulations of neurotransmission may underlie in part some of the early neuropsychiatric symptoms in PD preceding dysfunction of the nigrostriatal dopaminergic system.